Contents
Academy · Research Writing · Biosimilar Grant Proposals
Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget
A biosimilar proposal is judged on a different question from an originator-drug proposal. The question is not whether the molecule is effective, but whether the proposed analytical and clinical plan can demonstrate that it is not meaningfully different from a product of established effectiveness.
A biosimilar research grant proposal asks reviewers to fund work that establishes similarity, not novelty: the study exists to demonstrate that a proposed biologic has no clinically meaningful difference from an already-approved reference product, across analytical, non-clinical, and where required, clinical evidence. This framing affects almost every section of the proposal. Significance must be argued in terms of access, cost, and substitutability rather than a new mechanism of action. Innovation must be located in the comparative analytical method or in a more efficient clinical bridging design, since the underlying biology is, by definition, not new. Reviewers familiar with biosimilar science expect a proposal to demonstrate an understanding of this distinction before the methods are presented.
Learning objectives
- Why the significance and innovation arguments of a biosimilar proposal differ from those of an originator-drug proposal
- The evidence of biosimilarity required by regulators and its translation into a fundable study design
- The preliminary data and budget items that reviewers expect to see justified specifically in a biosimilar proposal
Common misconceptions
- “A biosimilar proposal requires only a smaller version of the clinical trial plan for an originator drug.” The FDA’s 2015 guidance on demonstrating biosimilarity describes a stepwise, totality-of-the-evidence approach that begins with extensive analytical characterization and non-clinical data, and adds clinical pharmacokinetic and, where needed, efficacy data only to address residual uncertainty. This evidentiary logic differs structurally from that of a standard efficacy-first drug trial.
Establishing significance when the underlying biology is not novel
A proposal's significance section must explain why the work matters, and for a biosimilar study that answer cannot rest on discovering a new target or mechanism, because the reference product has already established both4. The Biologics Price Competition and Innovation Act of 2009 created the abbreviated licensure pathway that makes biosimilar development possible in the United States precisely because duplicating full clinical development for every biologic was judged an inefficient use of resources once a reference product's safety and efficacy were already established4. A proposal's significance argument should therefore be built on what the biosimilar pathway itself is for: expanding patient access, lowering the cost of an already-proven therapy, or closing a specific analytical or clinical evidence gap that is currently blocking a particular biosimilar candidate from moving forward. Reviewers who work in this space regard significance sections that adopt originator-drug framing as an indication that the applicant has not engaged with the aims of biosimilar science1. A stronger significance section instead names the specific access or cost barrier that the candidate addresses (for example, a reference biologic whose cost has restricted use in a specific patient population or health system) and connects that barrier directly to what the proposed analytical or clinical bridging work will resolve, rather than describing the disease biology the originator product already treats as though that biology itself were the novel contribution.
Implications of the stepwise evidence requirement for study design
FDA's April 2015 guidance, "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product," lays out a stepwise approach: extensive structural and functional analytical comparison first, then animal and non-clinical data, then human pharmacokinetic and pharmacodynamic data, and clinical immunogenicity and efficacy data only where the earlier steps leave residual uncertainty that needs to be resolved2. The World Health Organization's 2009 guidelines on similar biotherapeutic products and the European Medicines Agency's guideline on similar biological medicinal products describe the same comparative logic, differing in regional detail but not in the underlying structure56. A fundable proposal should map its own study design onto this sequence explicitly: state which step the proposed work addresses, name the specific residual uncertainty it is designed to close, and explain why that step, rather than a full clinical efficacy trial, is the appropriate amount of evidence for the candidate at hand. A proposal that proceeds directly to a large clinical efficacy study without justifying why analytical and non-clinical data alone could not resolve the question invites reviewers to ask why the earlier, cheaper steps were not sufficient. This stepwise logic is also why a biosimilar proposal benefits from citing, rather than merely summarizing, the specific guidance passage it is designed against: a reviewer can rapidly verify whether a proposed study genuinely matches what the cited passage describes, which lends a credibility that a paraphrased, uncited description of “FDA's general approach” cannot provide.
FDA's companion 2014 quality guidance on demonstrating biosimilarity adds a further consideration that a proposal must address: analytical similarity is not a single pass/fail test but a tiered assessment across critical quality attributes, each ranked by its potential impact on clinical safety and efficacy, with the most clinically important attributes held to the most statistically rigorous comparison9. A later FDA draft guidance on statistical approaches to evaluating analytical similarity formalized this into specific equivalence-testing frameworks for the highest-tier attributes, which means a competitive proposal should specify not just which attributes it will measure but which statistical criterion, and which tier, each one will be judged against10. Reviewers familiar with this guidance will regard a proposal that treats every attribute identically, without this tiered logic, as insufficiently engaged with how FDA evaluates the evidence the study is designed to produce.
Structuring specific aims around residual uncertainty
General grant-writing guidance, including the widely used framework from Inouye and Fiellin's evidence-based guide to writing clinical research grant proposals, emphasizes that aims should be falsifiable, logically independent of one another, and clearly tied to a stated gap3. For a biosimilar proposal, each aim should correspond to one piece of the totality-of-evidence structure rather than restating the same comparability question three different ways: for example, an analytical-characterization aim establishing physicochemical and functional equivalence, a non-clinical or pharmacokinetic bridging aim addressing exposure comparability, and, only if required, an immunogenicity or clinical-outcome aim addressing a specific residual question the earlier aims could not close2. NIH's guidance on writing a specific aims page stresses that each aim should be a hypothesis a reviewer can see tested and falsified within the proposed study, not a restated goal, and this structure is as important for a biosimilar proposal as for any other application7.
NIH's peer-review process scores every application against five fixed criteria (significance, investigators, innovation, approach and environment), and a biosimilar proposal must address each one in terms specific to comparability science rather than generic translational-research language8. The approach criterion in particular is where a biosimilar proposal is most often marked down: reviewers scoring approach expect to see each aim's statistical analysis plan specified in enough detail to judge feasibility, including the equivalence margins or acceptance criteria that will be used to judge analytical similarity, not left as a placeholder to be determined once data collection begins810. Addressing the environment criterion for a biosimilar proposal typically means demonstrating access to the specific analytical platforms (such as orthogonal structural characterization methods) the proposed critical quality attribute testing requires, since this is equipment-intensive work in a way many other categories of clinical research are not.
Budget, timeline, and preliminary-data expectations
Reviewers scoring a biosimilar proposal expect preliminary data that demonstrate that the analytical platform can detect the kind of differences the study claims to be able to rule out, not merely a preliminary efficacy signal, since the entire argument of a biosimilar study rests on analytical sensitivity rather than a novel therapeutic effect2. Budget narratives should itemize the cost of reference-product acquisition across multiple lots, since biosimilarity assessment requires comparison against the natural lot-to-lot variability of the reference product itself, not a single reference sample2. NIH's Center for Scientific Review notes that study sections weigh feasibility heavily, and a biosimilar proposal's timeline should reflect the sequential, stepwise logic of the evidence plan rather than conducting every analytical, non-clinical and clinical work package in parallel from the outset8.
Where a proposed study includes a clinical pharmacokinetic bridging component, FDA's separate guidance on the clinical pharmacology data needed to support a biosimilarity demonstration specifies expectations around study population, dose selection, and the sensitivity of the PK endpoints chosen to detect a clinically meaningful difference, and a budget that has not accounted for the sample size such sensitivity requires is a common, avoidable weakness reviewers flag11. Preliminary data showing the proposed assay or pharmacokinetic model has adequate sensitivity in a smaller pilot dataset, submitted alongside the full proposal, is consistently the strongest single piece of evidence a biosimilar application can include, since it directly answers the feasibility question every other section of the proposal ultimately seeks to establish.
Key points
Key points
A biosimilar grant proposal is judged on how well it maps a stepwise, totality-of-the-evidence design onto a specific residual uncertainty, rather than on new discoveries about the underlying biology.
Practical application
Practical application
- The significance section should address access, cost and evidence gaps rather than mechanism. The proposal should state clearly which biosimilar-specific gap the study addresses and why that gap currently impedes development of the candidate.
- Each specific aim should correspond to one step of the stepwise evidence structure. Analytical, non-clinical/pharmacokinetic (PK) and clinical aims should be kept distinct, and the proposal should justify why the proposed step, rather than a larger one, provides the appropriate amount of evidence.
- The budget should explicitly account for reference-product lot variability. The cost of acquiring and testing multiple reference-product lots should be itemized, because reviewers will expect this biosimilar-specific cost to be justified.
Frequently asked questions
Not necessarily. FDA's stepwise approach explicitly allows the clinical evidence requirement to be reduced when analytical and non-clinical data sufficiently resolve uncertainty, and a proposal that argues this case well, rather than defaulting to a full efficacy trial, can be the stronger application.
Innovation in a biosimilar proposal is usually located in the comparative analytical method, a more sensitive or efficient bridging study design, or a novel way of resolving a specific residual uncertainty, not in the biology of the candidate itself.
Data showing that the analytical platform can reliably detect the kind of structural, functional or pharmacokinetic differences that the study design claims to rule out matter more than a preliminary efficacy signal.
Yes. Citing the specific guidance step that the study addresses, rather than describing biosimilarity testing in general terms, demonstrates to reviewers an understanding of the regulatory logic that the evidence plan must satisfy.
Guidance does not fix a single number, but budgets should explicitly account for testing more than one lot, since a single reference sample cannot represent the reference product's natural lot-to-lot variability.
References
- Inouye SK, Fiellin DA. An evidence-based guide to writing grant proposals for clinical research. Annals of Internal Medicine. 2005;142(4):274-282. read 10 October 2026. View on Annals of Internal Medicine
- US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Guidance for Industry. April 2015. read 10 October 2026. View on FDA.gov
- Inouye SK, Fiellin DA. An evidence-based guide to writing grant proposals for clinical research. Annals of Internal Medicine. 2005;142(4):274-282. (Publisher record) read 10 October 2026. View on Annals of Internal Medicine (publisher)
- US Congress. Biologics Price Competition and Innovation Act of 2009. Title VII of the Patient Protection and Affordable Care Act, Public Law 111-148. read 10 October 2026. View on Congress.gov
- World Health Organization Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). WHO Technical Report Series No. 977. 2009. read 10 October 2026. View on WHO.int
- European Medicines Agency. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). 2014. read 10 October 2026. View on EMA.europa.eu
- National Institutes of Health, Office of Extramural Research. Write Your Application. read 10 October 2026. View on grants.nih.gov
- National Institutes of Health, Center for Scientific Review. Peer Review Process. read 10 October 2026. View on public.csr.nih.gov
- US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product: Guidance for Industry. April 2015. read 10 October 2026. View on FDA.gov
- US Food and Drug Administration. Statistical Approaches to Evaluate Analytical Similarity: Guidance for Industry. 2017 (draft). read 10 October 2026. View on FDA.gov
- US Food and Drug Administration. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product: Guidance for Industry. December 2014. read 10 October 2026. View on FDA.gov
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget. Pubrica. https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/
Pubrica Academy. “Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget.” Pubrica, 10 Oct. 2026, pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/.
Pubrica Academy (2026) Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget. Pubrica. Available at: https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/ (Accessed: 15 October 2026).
Pubrica Academy. “Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget.” Pubrica. October 10, 2026. https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/
Pubrica Academy, ‘Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/> accessed 15 October 2026.
Pubrica Academy. Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/
Pubrica Academy, “Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/
@misc{/la_biosimilar_grant_proposal_essentials_2026,
author = {{Pubrica Academy}},
title = {Preparing a Biosimilar Research Grant Proposal: Significance, Evidence Structure, Aims and Budget},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/grant-proposal/what-should-you-know-before-you-write-a-biosimilar-grant-proposal-writing/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Biosimilar Proposal Mapping Worksheet
The proposed study design should be mapped onto the stepwise evidence structure before the specific aims are drafted.
[ ] Named the specific residual uncertainty this proposal is designed to close [ ] Mapped each aim to one step: analytical, non-clinical/PK, or clinical [ ] Justified why a full clinical efficacy trial is or is not required at this stage [ ] Itemized reference-product lot acquisition and multi-lot testing in the budget [ ] Cited the specific FDA/WHO/EMA guidance passage each aim is designed to satisfy [ ] Confirmed the significance section argues access/cost/evidence-gap, not novel mechanism
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s grant-writing and regulatory science team assists biosimilar developers in mapping a proposed study design onto the FDA’s stepwise evidence structure and in preparing specific aims, budgets and preliminary-data sections that reviewers can assess with confidence.